Advertisement

Topics

Harbin Gloria, WuXi Biologics Sign $818 Million Deal for Ex-China Rights to PD-1 Candidate

03:36 EDT 18 Aug 2017 | ChinaBio Today

Harbin Gloria Pharma and WuXi Biologics have entered an ex-China agreement for a PD-1 antibody with Arcus Biosciences of California's Bay Area in a deal worth up to $818 million. The PD-1 candidate, GLS-010, is currently in a China Phase I trial. Arcus will pay $18.5 million upfront for rights to GLS-010 in North America, Europe, Japan and other unspecified territories. It will also be liable for $422.5 million in development and regulatory milestones on combinations of GLS-010 and 11 Arcus products. Commercial milestones will add another $375 million to the agreement, and Arcus will also pay royalties on sales. More details....

Stock Symbols: (SHZ: 002437) (HK: 2269)

Share this with colleagues:

Original Article: Harbin Gloria, WuXi Biologics Sign $818 Million Deal for Ex-China Rights to PD-1 Candidate

NEXT ARTICLE

More From BioPortfolio on "Harbin Gloria, WuXi Biologics Sign $818 Million Deal for Ex-China Rights to PD-1 Candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...